Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

It is expected that the FDA will soon approve this generic as an obesity treatment since the obesity drug Saxenda has the ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

"Saxenda has the potential to help some of these ... At the moment the only drug for obesity on the market in Europe is Roche's Xenical (orlistat), a lipase inhibitor that has been available ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

Biocon and Zentiva receive EU approval for generic versions of Victoza (diabetes) and Saxenda (weight management). This marks a significant step in providing affordable treatment options for patients.

The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management ...

The study used the company's older GLP-1 agonist therapy Saxenda (liraglutide), which requires a daily injection, rather than its top-selling once-weekly obesity drug Wegovy (semaglutide), and ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

called Saxenda. “There are many people on this drug, and they will benefit by another generic version of it,” Dr. Harlan Krumholz, a cardiologist at Yale University and Yale New Haven Hospital ...

Stocks to buy in 2025: 66 ideas from top brokerages for your new year portfolio What does 2025 hold for India's IT services sector? 2025 may be the year of EVs in India, dominated by SUV launches The ...